Simon is new FDA anti-inflammatory division director
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lee Simon, MD, will start Nov. 19 as director of Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, replacing Acting Director Jonca Bull, MD. Simon, an associate professor of medicine at Harvard Medical School, was a principal investigator and lead author of Celecoxib Long-term Arthritis Safety Study. He has served as a consultant to Lilly, Forest, Aventis and Pharmacia/Searle
You may also be interested in...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: